COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2)

Protocol No
HUTCHISON-2019-013-GLOB1-FRESC
Principal Investigator
Ben George
Phase
III
Summary
This project is being done to find out whether Fruquintinib plus best supportive care is safe and is better than placebo plus best supportive care.
Description
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer (FRESCO-2)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL